Jay Bregman, CEO and co-founder of Andel, discusses how FDA’s action signals a broader regulatory recalibration aimed at protecting intellectual property and explores the second-order effects. Jay ...
In today's Pharmaceutical Executive Daily, Vertex Pharmaceuticals announces a $10 billion acquisition of Crinetics ...
In today's Pharmaceutical Executive Daily, AlzeCure Pharma announces a collaboration with QuantumCell ApS worth more than $2.2 billion for global rights to its Neurostore platform including ...
Bansi Nagji, CEO of PANTHERx Rare, explores how innovation is increasingly directed toward rare and orphan diseases, driven ...
Arthur G. Cook is Principal, ZS Associates.
Transaction terms include $85-per-share all-cash consideration (~$10B enterprise value) and an anticipated Q3 2026 close, contingent on customary conditions. Portfolio fit emphasizes serious, ...
Novartis is buying Myricx to internalize an NMTi-based ADC payload platform intended to expand ADC applicability and ...
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...
Troutman Pepper Locke senior associate Ryan Last explains when markets will start to significantly react to the upcoming pharma tariffs. In April of this year, President Trump announced plans to ...
Medicare GLP-1 Bridge provides Wegovy to eligible beneficiaries for $50/month through 2027, creating a defined access channel for obesity treatment previously largely excluded from Medicare coverage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results